Respiratory syncytial virus prophylaxis in preterm infants: A cost-effectiveness study from Turkey

Turkish Journal of Pediatrics

Volumn 54, Issue 4, 2012, Pages 344-351

  Öncel, Mehmet Yekta ^a   Mutlu, Banu ^a   Kavurt, Sumru ^b   Baş, Ahmet Yaǧmur ^b   Demirel, Nihal ^b   Akyol, Mesut ^c   Erdeve, Ömer ^a   Dilmen, Uǧur ^a,c  

^a Division of Neonatology   (Turkey)

^b Division of Neonatology   (Turkey)

^c YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

Cost effectiveness; Hospitalization; Palivizumab; Premature infants; Respiratory syncytial virus infections; Turkey

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD HEALTH CARE; CHILD HOSPITALIZATION; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY (TOPIC); NEWBORN; PREMATURITY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; TREATMENT DURATION; TURKEY (REPUBLIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CROSS INFECTION; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; TURKEY;

EID: 84873816630     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354: 847-852.
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282: 1440-1446.
3. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-1224.
4. Black C P. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003; 48: 209-233.
5. Boyce TG, Mellen BG, Mitchel Jr E F, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-870.
6. Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003; 22: 483-490.
7. Thomas M, Bedford-Russell A, Sharland M. Prevention of respiratory syncytial virus infection with palivizumab. Monaldi Arch Chest Dis 2000; 55: 333-338.
8. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
9. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997; 99: 93-99.
10. Feltes T F, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
11. Prescott WA Jr, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010; 28: 279-293.
12. RSV Proflaksisi için Türk Neonatoloji Derneǧi Önerileri. Türk Neonatoloji Derneǧi Bülteni 2007; 16: 13-15.
13. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162: 237-244.
14. Rietveld E, Steyerberg E W, Polder JJ, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child 2010; 95: 493-498.
15. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010; 11: 105-115.
16. Neovius K, Buesch K, Sandström K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Pædiatr 2011; 100: 1306-1314.
17. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-1729.
18. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-1216.
19. Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1447-1452.
20. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
21. Perrin KM, Bégué RE. Use of palivizumab in primary practice. Pediatrics 2012; 129: 55-61.
22. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011; 165: 498-505.
23. Vogel AM, Lennon DR, Broadbent R, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health 2002; 38: 550-554.
24. Figueras Aloy J, Quero J, Doménech E, et al.; Comité de Estándares de la Sociedad Española de Neonatología. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005; 63: 357-362.
25. Dizdar EA, Aydemir C, Erdeve O, et al. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit. J Hosp Infect 2010; 75: 292-294.